Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Zou, Xinhua; Xu, Qingyu; You, Ran; Yin, Guowen

Zou, Xinhua; Xu, Qingyu; You, Ran; Yin, Guowen.

Affiliation

Zou X; Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China.
Xu Q; Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China.
You R; Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China.
Yin G; Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China. jsnjgwy@163.com.

Adv Ther ; 40(4): 1686-1704, 2023 04.

Article de En | MEDLINE | ID: mdl-36805422

Sujet(s)
Mots clés

Hepatocellular carcinoma; Lenvatinib; PD-1 inhibitor; Portal vein tumor thrombus; Sorafenib; Transarterial chemoembolization

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Thrombose / Chimioembolisation thérapeutique / Carcinome hépatocellulaire / Tumeurs du foie Type d'étude: Observational_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Adv Ther Sujet du journal: TERAPEUTICA Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google